Elitsa Ivanova Boneva

Ms. Elitsa Ivanova Boneva


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2025 in Immuno
Verified
Journal Article
Open access
PDF file
EBElitsa Ivanova Boneva
Elitsa Ivanova Boneva
VSVelizar Shivarov
Velizar Shivarov
MIMilena Ivanova
Milena Ivanova
The immune system’s ability to detect and eliminate transformed cells is a critical factor in suppressing cancer development. However, immune surveillance in tumors is often disrupted by various immune escape mechanisms, many of which remain poorly understood. The Natural Killer Group 2D (NKG2D) receptor is an activating receptor expressed on natural killer (NK) cells and cytotoxic T lymphocytes. It can recognize and bind with varying affinities to a wide range of structurally diverse ligands, including MHC class I chain-related proteins A and B (MICA and MICB) and members of the ULBP family (ULBP1-6). The expression of these ligands plays a crucial role in immune antitumor responses and cancer immunoevasion mechanisms. Some evidence suggests that functional polymorphisms in the NKG2D receptor and the genes encoding its ligands significantly influence HLA-independent cancer immunosurveillance. Consequently, the NKG2D-NKG2D ligands (NKG2DLs) axis represents a promising target for developing novel therapeutic strategies. This review aims to provide a general overview of the role of NKG2D and its ligands in various malignancies and explore their potential in advancing personalized cancer treatment protocols.

22 October 2026 in Oral
Verified
Journal Article
Open access
PDF file
VSVelizar Shivarov
Velizar Shivarov
EBElitsa Ivanova Boneva
Elitsa Ivanova Boneva
EDElitsa Deliverska
Elitsa Deliverska
SYStanislav Yordanov
Stanislav Yordanov
SSSvetoslav Slavkov
Svetoslav Slavkov
MIMilena Ivanova
Milena Ivanova
Background/Objectives: Natural killer group 2D (NKG2D), encoded by KLRK1, contributes to the immune recognition of stressed and transformed epithelial cells through interactions with MICA and MICB ligands. Previous work from our group implicated MICA/MICB variation in Bulgarian patients with oral squamous cell carcinoma (OSCC), but the receptor-side contribution of KLRK1 has not been examined in the same disease context. Methods: Five candidate KLRK1 single-nucleotide polymorphisms were initially evaluated in 69 OSCC patients and 105 Bulgarian controls. After anatomical review, one maxillary sinus and one soft palate case were excluded from the primary strict OSCC cohort. Hardy–Weinberg equilibrium, genotype call rates, differential missingness, genotype and allele counts, additive logistic regression, MICA-129-adjusted models, age-overlap sensitivity analyses, and four-marker haplotypes were assessed. Results: The final primary cohort included 67 strict OSCC cases and 105 controls. rs2255336 deviated significantly from Hardy–Weinberg equilibrium in controls and was excluded from primary inference. Among the four retained variants (rs2617170, rs2246809, rs2617160, and rs1049174), no statistically detectable association with OSCC was observed after adjustment for age and sex or after additional adjustment for MICA-129 genotype. The four-marker haplotype analysis was also non-significant. Conclusions: In this QC-aware exploratory analysis, the KLRK1 variants retained after Hardy–Weinberg filtering were not detectably associated with OSCC. These negative findings should be interpreted cautiously because of the limited power, differential genotype missingness, age and sex imbalance, absence of ancestry principal components, and lack of tobacco, alcohol, and HPV data.